Shares of Santarus Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, surged in trading on Friday after the company agreed to be acquired by Salix Pharmaceuticals Ltd. (NASDAQ: SXLP). The two companies entered into a definitive agreement under which SLXP will acquire all outstanding shares of Santarus for $32 per share in cash. The offer price from Salix represents a premium of 36% over Santarus’ closing price on November 6, 2013. Santarus shares ended the day 37.60% higher at $31.95 on above average volume of 45.22 million. SLXP shares, meanwhile, ended the day 17.80% higher at $84 on above average volume of 6.64 million.